Right now, a Medicare enrollee who fills a Wegovy prescription without supplemental coverage faces a list price north of $1,300 a month. Starting July 1, 2026, a new federal program will cap that cost at $50.
The program is called the Medicare GLP-1 Bridge, and the Centers for Medicare and Medicaid Services (CMS) will operate it through December 31, 2027. It locks in a flat $50 monthly copay for four specific products: Wegovy injection, Wegovy tablets, Zepbound KwikPen, and Foundayo (survodutide, manufactured by Boehringer Ingelheim), which won FDA approval for chronic weight management in late 2025. No other weight-loss medications are included. Ozempic and Mounjaro, even when prescribed off-label for obesity, do not qualify.
The stakes are enormous. Obesity affects roughly 42% of U.S. adults, according to the CDC’s most recent prevalence data, and rates are even higher among adults 60 and older. For Medicare beneficiaries who have watched GLP-1 drugs transform obesity care while remaining financially out of reach, the Bridge is the first real opening. But it comes with eligibility hurdles, a firm expiration date, and no guarantee of what follows.
How the $50 copay actually works
CMS negotiated directly with the manufacturers of the four covered drugs to set a net price of $245 per monthly supply. The beneficiary pays $50 at the pharmacy counter, regardless of which Part D plan they carry or what coverage phase they have reached. The remaining $195 is absorbed through the manufacturer agreements and existing plan structures, not billed to the patient.
The Bridge is not a separate insurance product. Seniors still need active enrollment in a Medicare Part D plan or a Medicare Advantage plan with drug coverage, and they still need to fill prescriptions at in-network pharmacies. What changes is the final price: instead of plan-specific copays or coinsurance that can swing from $200 to well over $1,000 depending on the coverage phase, the cost is standardized at $50 for these four products.
Because the Bridge layers on top of existing Part D benefits rather than replacing them, beneficiaries do not need to switch plans or submit a separate enrollment form. An active Part D benefit and a qualifying prescription are the entry tickets.
The catch: a prescriber screening most patients won’t see, but some will
CMS requires that the prescribing physician not appear on the agency’s preclusion list, a federal database of providers barred from Medicare Part D participation due to sanctions, license revocations, or other enforcement actions. If a patient’s doctor is on that list, the Bridge copay does not apply, period.
For most beneficiaries, this screening is invisible. Pharmacies and plans verify prescriber status automatically when processing claims, and the vast majority of licensed physicians are not precluded. The problem surfaces in places where provider options are already scarce. In rural counties and medically underserved communities, patients may depend on one or two local doctors. If one of those physicians carries a preclusion flag, the affected senior would need to establish care with a different prescriber before accessing the $50 price. That process can mean long drives or weeks-long waits for a new-patient appointment.
“I have patients who drive 45 minutes each way just to see me,” said Dr. Angela Torres, a family medicine physician in rural eastern Kentucky who treats a large Medicare panel. “If their only local prescriber is flagged, they are not going to be able to get this benefit without real hardship. The screening makes sense on paper, but it assumes people have choices that a lot of my patients simply don’t have.”
CMS designed the Bridge to be simple at the pharmacy counter. But this backstop requirement adds a layer of administrative friction that will land hardest on patients with the fewest alternatives.
The bigger catch: 18 months and a ticking clock
The preclusion-list screening is a procedural hurdle. The more consequential limitation is the program’s expiration date.
CMS has been explicit that the Bridge is a stopgap. The agency built it to run for 18 months while it launches a separate, longer-term experiment called the Balance Model, housed within the CMS Innovation Center. The Balance Model is designed to answer the question that has dogged policymakers since GLP-1 drugs became blockbusters: does covering expensive weight-loss medications for Medicare patients actually reduce total spending over time by preventing hospitalizations, heart attacks, joint replacements, and other costly complications of obesity?
There is strong clinical evidence suggesting it could. Novo Nordisk’s SELECT trial, published in The New England Journal of Medicine in 2023, found that semaglutide reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and obesity. But that trial studied a specific high-risk population over a defined period. Translating those results into real-world Medicare savings across a broader, older population is a different calculation, and CMS wants its own data before committing to permanent coverage.
“The Bridge buys CMS time, but it also creates a promise,” said Tricia Neuman, executive vice president at the Kaiser Family Foundation and a senior adviser on Medicare policy. “Millions of seniors could start these drugs at $50 a month and then face a cliff in January 2028. The political and clinical pressure to extend or replace the program will be intense.”
The Bridge, then, serves two purposes at once. It gives patients affordable access to GLP-1 drugs now, and it generates the enrollment and utilization data CMS needs to evaluate whether a permanent benefit pencils out. According to CMS guidance published alongside the Bridge announcement, providers participating in related payment models are expected to coordinate follow-up care, including nutrition counseling and physical activity support, to strengthen outcomes.
What patients should sort out before July 1
Several practical details remain unresolved as of June 2026. CMS has not published projected enrollment figures, so it is unclear how many beneficiaries the agency expects to use the Bridge in its first year. The agency also has not released detailed guidance on how the program interacts with Medicaid for dual-eligible beneficiaries, those enrolled in both Medicare and Medicaid, who represent a disproportionate share of the Medicare population with obesity-related chronic conditions.
Eligibility criteria beyond the preclusion check matter, too. According to the FDA-approved labeling for the covered drugs, beneficiaries need a documented diagnosis of obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. CMS has not yet published separate Bridge-specific clinical criteria, so prescribers should follow the FDA indications as the baseline standard until further guidance is issued. Patients currently taking Ozempic or Mounjaro for diabetes should talk to their doctors about whether switching to a Bridge-eligible product makes clinical sense, since those diabetes-indicated drugs are not part of this program.
Supply is another open question. GLP-1 medications have been subject to intermittent shortages since 2023, driven by surging demand that outpaced manufacturing capacity. Novo Nordisk and Eli Lilly have both invested billions in new production facilities, but adding millions of Medicare patients to the demand pool could test supply chains again. CMS has not publicly addressed how the Bridge would function during a shortage.
And then there is the question no one at CMS has answered yet: what happens on January 1, 2028? GLP-1 drugs for obesity are prescribed as ongoing therapy. Clinical evidence consistently shows that patients who discontinue these medications regain a substantial portion of lost weight, often within 12 months. A patient who starts Wegovy under the Bridge in mid-2027 could have just six months of $50 copays before facing a return to list-price costs, unless CMS extends the program or the Balance Model produces results that justify making coverage permanent.
How to prepare for the Bridge before the July 1 start date
The Medicare GLP-1 Bridge is the most aggressive step the federal government has taken to make weight-loss drugs affordable for seniors. Dropping the monthly cost from four figures to $50 will put medications like Wegovy and Zepbound within reach for patients who have spent years priced out of a treatment their doctors recommended.
But the program’s 18-month window, its prescriber screening requirement, and the absence of a guaranteed successor mean that patients and physicians need to plan with the end date in mind. Seniors considering the Bridge should confirm their prescriber’s status well before July 1, verify their Part D enrollment, and have a direct conversation with their doctor about what a treatment plan looks like if the discount disappears at the end of 2027. Building in lifestyle changes, monitoring metabolic markers, and discussing contingency options now will matter more than the copay itself if the clock runs out.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
